Hormone-dependent prostate cancer is a condition where cancer cells rely on male hormones to grow and spread. The main goal of treatment is to control tumor growth by reducing or blocking these hormones, helping patients live longer and maintain their quality of life. Medical professionals have developed various approaches, from well-established methods to new experimental therapies being tested in clinical trials.

What Does Treatment Actually Aim to Achieve?

When dealing with hormone-dependent prostate cancer, treatment focuses primarily on controlling how the disease behaves rather than simply eliminating it. The cancer cells need testosterone and other androgens—male sex hormones—to survive and multiply. By reducing the levels of these hormones or preventing them from reaching cancer cells, doctors can slow down or even halt tumor growth for extended periods.

The treatment approach depends heavily on several factors unique to each patient. The stage of the cancer, whether it has spread beyond the prostate gland, the patient’s age and overall health, and the presence of other medical conditions all influence which therapy might work best. Some men receive hormone therapy alone, while others combine it with radiation or other treatments to improve their chances of controlling the disease.

Medical societies and cancer organizations worldwide have established guidelines based on years of research and patient outcomes. These recommendations help doctors choose the most appropriate treatments for each situation. At the same time, researchers continue exploring new medications and treatment combinations through clinical trials, offering hope for even better options in the future.

Standard Treatment Approaches

The foundation of treating hormone-dependent prostate cancer is androgen deprivation therapy, commonly abbreviated as ADT. This treatment works by dramatically reducing the amount of testosterone available to cancer cells. Since testosterone acts like fuel for these cells, cutting off the supply causes them to die or grow much more slowly. Nearly all testosterone in men is produced by the testicles, with smaller amounts coming from the adrenal glands.

There are several methods to achieve androgen deprivation. The most common involves medications called LHRH agonists and antagonists, also known as GnRH agonists and antagonists. These medicines block signals from the brain that normally tell the testicles to produce testosterone. Brand names and specific drugs in this category include compounds that are typically given as injections every few weeks or months. The drugs work by affecting the luteinizing hormone-releasing hormone pathway, which is the body’s natural system for controlling testosterone production.

Another medication approach uses antiandrogens. These drugs don’t stop testosterone production but instead prevent the hormone from attaching to cancer cells. Antiandrogens are often prescribed together with LHRH agonists because LHRH medications can initially cause a brief spike in testosterone levels before bringing them down, a phenomenon that antiandrogens help manage.

In some situations, particularly in the past, doctors performed a surgical procedure called orchiectomy to remove the testicles or the parts that produce testosterone. This immediately and permanently lowers testosterone levels in the body. However, most patients and doctors today prefer medication-based approaches because they avoid permanent surgery and can be stopped if needed.

For men with metastatic hormone-sensitive prostate cancer—meaning the cancer has spread to other parts of the body but still responds to hormone treatment—medical guidelines now recommend combining standard ADT with additional medications. These combinations have been shown in clinical trials to extend the time before disease progression and improve survival compared to using ADT alone. One approach adds drugs called androgen receptor pathway inhibitors to standard hormone therapy. These newer medications, including abiraterone, apalutamide, darolutamide, and enzalutamide, either block androgen receptors more completely or prevent the body from making any androgens at all, including those produced outside the testicles.

Another combination approach involves adding chemotherapy with docetaxel to hormone therapy. This combination has proven particularly beneficial for patients with higher-volume or more aggressive disease that has spread to multiple sites in the body.

The duration of hormone therapy varies considerably. For men receiving it alongside radiation for localized cancer, treatment might last anywhere from several months to two years, depending on how aggressive the cancer appears. Research has shown that men with high-risk features benefit most from longer durations of hormone therapy—up to 24 months—while those with intermediate-risk cancer may do well with shorter courses of four to six months. For advanced or metastatic disease, hormone therapy is often continued indefinitely, although some doctors use an intermittent approach where treatment is stopped and restarted based on monitoring results.

Healthcare providers monitor the effectiveness of hormone therapy primarily through blood tests measuring prostate-specific antigen, or PSA. PSA is a protein produced by prostate cells, and its levels typically drop dramatically when hormone therapy is working. Rising PSA levels over time can indicate that the cancer is becoming resistant to treatment. Doctors also monitor testosterone levels to ensure they remain very low during treatment.

Managing Side Effects of Standard Treatment

Because testosterone affects many body systems beyond the prostate, reducing it causes various side effects that can significantly impact daily life. Understanding these effects helps patients prepare and manage them more effectively.

Hot flushes are among the most common and bothersome side effects, experienced by many men on hormone therapy. These sudden feelings of intense heat, often accompanied by sweating and redness, occur because low testosterone affects the body’s temperature regulation system. They can happen multiple times throughout the day and night, sometimes disrupting sleep.

Changes in body composition are also typical. Men often notice weight gain, particularly around the abdomen, and loss of muscle mass and strength. These changes happen because testosterone normally helps maintain muscle tissue and regulates how the body stores fat. The metabolic shifts can also increase the risk of developing diabetes and cardiovascular problems over time, making it important for patients to maintain healthy eating habits and stay physically active.

Bone health becomes a concern during long-term hormone therapy. Testosterone helps maintain bone density, so its absence can lead to osteoporosis—a condition where bones become thin and fragile, increasing fracture risk. Doctors often recommend calcium and vitamin D supplements, and may prescribe medications specifically to protect bones during treatment.

Sexual function is profoundly affected. Most men experience reduced sex drive and difficulty achieving or maintaining erections. These changes stem from the direct effects of low testosterone on sexual response systems. Some men also develop breast swelling and tenderness, a condition called gynaecomastia, because the hormone balance shifts.

Fatigue is another frequent complaint. Men describe feeling tired even after adequate rest, and this exhaustion can affect their ability to work, exercise, or engage in social activities. Some people also report problems with memory, concentration, and thinking clearly, sometimes called “brain fog.”

Emotional changes can occur as well. Some men experience mood swings, increased irritability, or symptoms of depression. These may result from hormonal changes themselves or from coping with cancer and its side effects.

Healthcare teams can offer various strategies to reduce these side effects. Exercise programs that include both aerobic activity and strength training help maintain muscle mass, bone density, and overall fitness while improving mood and energy. Dietary counseling can address weight gain and metabolic changes. For hot flushes, certain medications originally developed for other conditions have been found helpful. Medications to protect bone health can be prescribed when needed. Support groups and counseling services help men cope with emotional and psychological challenges.

Treatment in Clinical Trials

While standard hormone therapy remains effective for many patients, researchers continually work to develop better treatments with fewer side effects or that work for cancers that become resistant to current therapies. Clinical trials test these new approaches before they become widely available.

Clinical trials follow a structured process divided into phases. Phase I trials primarily assess whether a new treatment is safe and determine the appropriate dose. These studies involve small numbers of participants and carefully monitor for any harmful effects. Phase II trials examine whether the treatment actually works against the cancer—does it shrink tumors, lower PSA levels, or slow disease progression? These studies involve more patients and provide early evidence of effectiveness. Phase III trials compare the new treatment directly against current standard treatments in large groups of patients to determine if it offers better outcomes.

Several promising approaches are currently being investigated in clinical trials for hormone-dependent prostate cancer, particularly for disease that has spread beyond the prostate.

Next-Generation Androgen Receptor Blockers

Scientists have developed newer medications that target the androgen receptor in different or more powerful ways. These drugs recognize that even when testosterone levels are very low, cancer cells sometimes find ways to activate their androgen receptors through alternative pathways. The medications work by binding to the receptor so tightly that androgens cannot attach, or by preventing the receptor from entering the cell nucleus where it would normally activate cancer-promoting genes.

Several of these agents have already moved from clinical trials to approved treatments after demonstrating benefits. Trials continue exploring whether combining multiple receptor blockers or using them earlier in treatment might improve outcomes even further.

Drugs That Block Androgen Production

Another research direction involves medications that stop the body from making androgens anywhere—not just in the testicles but also in the adrenal glands and even within cancer cells themselves. Some prostate cancer cells develop the ability to produce their own testosterone, allowing them to continue growing despite very low testosterone levels in the bloodstream.

Abiraterone is one such medication that blocks an enzyme called CYP17A1, which is essential for making androgens throughout the body. It must be taken with prednisone, a steroid medication, because blocking androgen production affects other hormone systems. Clinical trials that led to abiraterone’s approval showed it extended survival when added to standard hormone therapy for metastatic hormone-sensitive prostate cancer.

Researchers continue testing similar drugs that target different steps in the androgen production pathway, hoping to find even more effective ways to deprive cancer cells of hormones they need.

Combination Therapies

Much current research focuses on combining different treatment types to attack cancer from multiple angles simultaneously. For example, trials are examining whether adding immunotherapy drugs to hormone therapy might help the immune system recognize and destroy cancer cells more effectively. These combinations are particularly interesting for cancers with certain genetic characteristics that might make them more responsive to immune-based treatments.

Other studies combine hormone therapy with drugs targeting specific molecular pathways that cancer cells use to survive and grow. For instance, some trials investigate adding medications that interfere with DNA repair mechanisms in cancer cells, particularly for tumors with inherited genetic mutations like BRCA1 or BRCA2.

Targeted Therapies Based on Genetic Testing

As scientists better understand the genetic changes that occur in prostate cancer, they can develop treatments targeting specific abnormalities. Genetic testing of tumor samples can identify mutations, gene fusions, or other alterations that might be vulnerable to particular drugs.

Clinical trials are testing various targeted agents matched to specific genetic profiles. This approach, sometimes called precision medicine or personalized medicine, aims to give patients treatments most likely to work for their specific cancer type rather than using a one-size-fits-all approach.

Novel Drug Delivery Methods

Researchers are also exploring better ways to deliver existing or new medications. Some trials test extended-release formulations that require less frequent injections, improving convenience for patients. Others investigate whether different dosing schedules or combinations might reduce side effects while maintaining effectiveness.

Eligibility for clinical trials typically depends on factors including the cancer’s stage, previous treatments received, overall health, and specific characteristics of the tumor. Trials are conducted at major cancer centers and academic hospitals in locations throughout the United States, Europe, and other regions worldwide. Patients interested in participating can discuss options with their oncologists or search clinical trial databases to find studies accepting participants with their specific situation.

Intermittent Treatment Approaches

Some clinical trials examine whether hormone therapy can be given intermittently—stopping and starting rather than continuously—to reduce side effects while maintaining cancer control. The concept is that giving the body breaks from treatment might allow side effects like fatigue, sexual dysfunction, and bone loss to improve during off-treatment periods. During these breaks, testosterone levels can recover somewhat, potentially improving quality of life.

Early results suggest that for carefully selected patients, intermittent therapy might provide similar cancer control outcomes to continuous treatment while offering better quality of life. However, this approach requires careful monitoring with regular PSA tests to determine when treatment should resume.

Most Common Treatment Methods

• Androgen Deprivation Therapy (ADT)
  • LHRH agonists and antagonists given as injections to block testosterone production by the testicles
  • Antiandrogens that prevent testosterone from reaching cancer cells
  • Surgical removal of testicles (orchiectomy) to permanently lower testosterone levels
  • Can be given continuously or intermittently depending on cancer characteristics
• Androgen Receptor Pathway Inhibitors
  • Abiraterone, which blocks androgen production throughout the body including in cancer cells
  • Apalutamide, darolutamide, and enzalutamide, which block androgen receptors more completely than older antiandrogens
  • Often combined with standard ADT for metastatic hormone-sensitive disease
  • Proven to extend time before disease progression and improve survival
• Combination Therapy
  • Hormone therapy combined with radiation for localized or locally advanced cancer
  • ADT plus androgen receptor pathway inhibitors for metastatic disease
  • Hormone therapy combined with docetaxel chemotherapy for higher-volume metastatic cancer
  • Treatment duration typically ranges from several months to indefinite depending on disease stage
• Supportive Treatments
  • Bone-strengthening medications to prevent osteoporosis during long-term hormone therapy
  • Medications to manage hot flushes and other hormone-related side effects
  • Exercise and nutrition programs to maintain muscle mass and manage weight
  • Counseling and support services for emotional and psychological well-being